Systematic Literature Review Living SLR Meta-Analysis Evidence Grading Medical Affairs KOL Intelligence Congress Intelligence Medical & Scientific Writing HEOR Market Access Investor & BD Reports Evidence Marketplace Clinical Development Competitive Intelligence Always-on Monitors
Pricing Platform Skills Contact
Sign in Request a Demo
Evidara · Chain CI — Competitive Intelligence

Your competitor's evidence.
Before your next board meeting.

Chain CI tracks competitor publication landscape, active pipeline trials, and head-to-head evidence for up to 10 products simultaneously — returning a complete competitive intelligence brief in 20 minutes, categorized by evidence type and sourced to PMID and NCT ID.

Request a Demo → Explore free →
10 products
Own product + competitors analyzed simultaneously on every Chain CI run
6 types
Evidence categorized: RCT, RWE, safety, HTA, new indication, health economics
H2H detect
Head-to-head studies automatically identified across PubMed and Europe PMC
PDF+PPTX
Competitive brief exported slide-ready for board presentations and payer meetings
The competitive intelligence gap

Three surveillance problems that leave
your commercial team flying blind.

Competitive intelligence for pharmaceutical products requires continuous monitoring across publications, trials, and payer decisions — work that currently falls through the cracks between commercial and medical teams.

01 — Publication Monitoring
Tracking competitor publications across journals is a full-time job
A competitor in a major indication can generate 50–200 publications per year across clinical, RWE, safety, and economic evidence types. No team has the bandwidth to read every paper — meaning new competitor RCT data, safety signals, or HTA submissions get missed.
~3–4 days per competitor per quarter
02 — Pipeline Threats
Knowing which competitor trials will read out in 12 months
ClinicalTrials.gov holds over 500,000 registered studies. Identifying which competitor Phase 2/3 trials are active in your indication — and when they're likely to read out — requires manual registry screening that commercial teams rarely have time to run systematically.
Missed pipeline threats
03 — Head-to-Head Evidence
Finding comparative studies buried across databases
Studies that directly compare your product against a competitor — or indirect comparisons via NMA — are scattered across PubMed, conference proceedings, and grey literature. Payers ask about them in every meeting. Finding them takes days.
Weak payer meeting preparation
How Evidara solves it

Complete competitive surveillance
in a single Chain CI run.

Publication Landscape

Competitor evidence categorized by type

Chain CI queries PubMed and Europe PMC for each product simultaneously, categorizing results into evidence types: efficacy RCT, safety, real-world evidence, new indication, HTA submission, label update, pediatric, and health economics — giving commercial teams a structured view of where competitor evidence is building.
PubMed + Europe PMC per product, up to 6 competitors
Publications categorized by evidence type automatically
Recency filter — new publications surfaced first
PMID citation on every publication listed
Pipeline Intelligence

Active competitor trials and readout timeline

ClinicalTrials.gov is queried for active Phase 2 and Phase 3 competitor trials — returning status, estimated completion dates, primary endpoints, and enrollment targets. Pipeline threats are flagged by estimated readout window so commercial and market access teams can plan responses.
Active Phase 2/3 competitor trials by product
Estimated completion dates and readout windows
Primary endpoints and enrollment numbers
NCT ID on every trial returned
Head-to-Head Detection

Comparative evidence automatically identified

Chain CI automatically detects studies containing both your product and a named competitor in the title or abstract — direct head-to-head trials, indirect treatment comparisons, and NMA analyses. These are flagged separately so payer meeting preparation teams can review them first.
Head-to-head studies flagged — direct and indirect
NMA publications and indirect comparisons identified
Evidence gaps where no comparative data exists
GRADE evidence level per comparative finding
Illustrative example

GLP-1 competitive landscape — semaglutide vs. tirzepatide

Chain CI builds a competitive evidence landscape for a drug against its named comparators — retrieving active competitor trials from ClinicalTrials.gov, grouping the publication landscape by evidence type, surfacing head-to-head and indirect comparisons, and calling out where head-to-head evidence does not exist.

Run this analysis yourself →
"Build a competitive intelligence brief for semaglutide vs. tirzepatide, dulaglutide, and liraglutide in type 2 diabetes — publication landscape, active trials, and head-to-head evidence"
Competitor trial landscape — active studies by phase, with registered readout timing where available
Head-to-head and indirect comparison studies identified and labelled by comparison type
HTA submissions detected per market — CADTH, PBAC, G-BA, HAS
Evidence gaps stated explicitly where no head-to-head RCT exists for an indication
Competitor publications categorized by evidence type — RCT efficacy, RWE, safety, HTA
Chain CI · Illustrative example — not a live run · PROVISIONAL, requires expert review
Get started

See your competitive landscape
built live in the demo.

We'll run a live Chain CI analysis on your asset and its key comparators — returning real publication data, active pipeline trials, and head-to-head evidence. Your indication. Live data.

Request a Demo → Explore free →